Jacobs Levy Equity Management’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-20,777
| Closed | -$191K | – | 1176 |
|
|
2021
Q2 | $191K | Sell |
20,777
-300,263
| -94% | -$1.75M | ﹤0.01% | 993 |
|
|
2021
Q1 | $1.6M | Buy |
321,040
+87,500
| +37% | +$423K | 0.01% | 642 |
|
|
2020
Q4 | $1.01M | Buy |
233,540
+216,458
| +1,267% | +$880K | 0.01% | 718 |
|
|
2020
Q3 | $73K | Buy |
+17,082
| New | +$71.4K | ﹤0.01% | 1003 |
|
|
2020
Q2 | – | Sell |
-16,038
| Closed | -$64K | – | 1194 |
|
|
2020
Q1 | $64K | Buy |
+16,038
| New | +$136K | ﹤0.01% | 972 |
|
|
2018
Q3 | – | Sell |
-57,652
| Closed | -$614K | – | 1105 |
|
|
2018
Q2 | $614K | Buy |
57,652
+36,741
| +176% | +$358K | 0.01% | 759 |
|
|
2018
Q1 | $181K | Buy |
+20,911
| New | +$183K | ﹤0.01% | 940 |
|
|
2017
Q2 | – | Sell |
-22,663
| Closed | -$160K | – | 1045 |
|
|
2017
Q1 | $160K | Sell |
22,663
-9,600
| -30% | -$60.1K | ﹤0.01% | 819 |
|
|
2016
Q4 | $137K | Sell |
32,263
-10,400
| -24% | -$50.3K | ﹤0.01% | 867 |
|
|
2016
Q3 | $213K | Sell |
42,663
-8,000
| -16% | -$33.8K | ﹤0.01% | 895 |
|
|
2016
Q2 | $179K | Buy |
50,663
+17,800
| +54% | +$65.4K | ﹤0.01% | 1027 |
|
|
2016
Q1 | $113K | Sell |
32,863
-12,445
| -27% | -$44K | ﹤0.01% | 1025 |
|
|
2015
Q4 | $154K | Buy |
+45,308
| New | +$210K | ﹤0.01% | 716 |
|
Other funds holding KIN
Jacobs Levy Equity Management's KIN Position: Q3 2021 in Review
Jacobs Levy Equity Management sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 20,777 shares — an estimated $191K sold.
Jacobs Levy Equity Management first reported a position in KIN in Q4 2015 and held it in 13 quarters. The position peaked at $1.6M in Q1 2021. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- Jacobs Levy Equity Management reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Jacobs Levy Equity Management sold 20,777 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $191K.
- Jacobs Levy Equity Management first reported a position in Kindred Biosciences, Inc. in Q4 2015 and held it in 13 quarters.
- Jacobs Levy Equity Management's Kindred Biosciences, Inc. position peaked at $1.6M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.